# A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

> **NCT02561234** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aeglea Biotherapeutics** · enrollment: 98 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Co-ArgI-PEG

## Key facts

- **NCT ID:** NCT02561234
- **Lead sponsor:** Aeglea Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2021-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561234, "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02561234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*